close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Almirall, S.A.

News headline image
EADV 2026: Long-Term Disease Control for up to Five Years in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Lebrikizumab
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Advances Skin Science and Shares New Evidence Across Its Dermatology Portfolio at EADV 2026
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Enters Collaboration With CrystalO for the Discovery and Development of Novel Small Molecules in Medical Dermatology
From Almirall, S.A.
Via Business Wire
News headline image
Almirall H1 2026 Results
From Almirall, S.A.
Via Business Wire
News headline image
Almirall’s 2025 Results
From Almirall, S.A.
Via Business Wire
News headline image
Lebrikizumab delivered long-term disease control for up to four years in patients with moderate-to-severe atopic dermatitis
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Announces the Approval of Seysara® in China for the Treatment of Moderate-to-Severe Acne
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Announces “LumiNE”, a Phase III Clinical Study Assessing the Efficacy of Lebrikizumab for the Treatment of Nummular Eczema
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Presents R&D Pipeline Advances Supported by Sustained Growth and Leadership in Medical Dermatology at J.P. Morgan Healthcare Conference
From Almirall, S.A.
Via Business Wire
News headline image
Almirall’s 2025 9M Results
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 2025
From Almirall, S.A.
Via Business Wire
News headline image
EADV 2025: Almirall Advances Skin Science and Leads Innovation for Holistic Patient Care in Medical Dermatology
From Almirall, S.A.
Via Business Wire
News headline image
Almirall H1 2025 Results
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Q1 2025 Results
From Almirall, S.A.
Via Business Wire
News headline image
AAD 2025: Almirall presents early-stage pipeline progress and real-world evidence on demonstrating AK treatment success and patient satisfaction with Tirbanibulin
From Almirall, S.A.
Via Business Wire
News headline image
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline
From Almirall, S.A.
Via Business Wire
News headline image
Almirall’s Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology Portfolio, Fuelled by Biologics Growth
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
From Almirall, S.A.
Via Business Wire
News headline image
Almirall’s H1 2024 Results: Almirall Delivers Strong Performance in the First Half of 2024, Achieving Net Sales Growth of 6.7% Driven by Its European Dermatology Business and Accelerating Biologics Sales
From Almirall, S.A.
Via Business Wire
News headline image
Almirall Delivers Strong Start of 2024 – Q1 Net Sales Growth of 6.6% Overall and 18% in the European Dermatology Business, Driven by Biologics and Solid Performance of Broad Product Portfolio
From Almirall, S.A.
Via Business Wire
News headline image
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological Diseases
From Almirall, S.A.
Via Business Wire
News headline image
Almirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology business
From Almirall, S.A.
Via Business Wire
News headline image
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
From Almirall, S.A.
Via Business Wire
News headline image
Almirall’s First Quarter 2023 Results
From Almirall, S.A.
Via Business Wire
News headline image
Almirall’s Full-Year 2022 Results
From Almirall, S.A.
Via Business Wire
News headline image
Almirall’s Nine-month 2022 Results
From Almirall, S.A.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.